Since 2012, the National Center for Tumor Diseases (NCT) Heidelberg – a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and German Cancer Aid (DKH) – has been organizing a charity run against cancer. This year, Proteona teamed up with Aescuvest for the good cause.
Running All By Oneself, United in Spirit
In NCT’s “Run Against Cancer” the participants could pick a distance between 2.5 kilometres and a half-marathon. In the face of Covid-19, all runners had to compete individually – while sharing one common goal: The kilometers run were converted into hard currency by sponsors such as SAP, Prominent and the Klaus Tschira Foundation and Affimed.
Proteona Sets the Pace – Internationally
Along with the Aescuvest team, Proteona sent 80 participants into the field (including our furry friends and even a robot), registering a combined 546 kilometers for the good cause in 27 cities on five continents. In total, 8,976 runners took part on seven continents (yes, there was a team in Antarctica), covering almost 120,000 kilometers. The sporty version of crowdfunding raised an impressive €75,000 for cancer research at the NCT Heidelberg.
“We are very happy to have contributed with our combined forces so that one day mankind is catching up in this race against cancer. This sore muscle pays off,” said Andreas Schmidt, CEO of Proteona.
According to Dirk Jäger, Managing Director at the NCT Heidelberg and head of “Medical Oncology” at the University Hospital (UKHD), the funds raised by the charity run enable the support of innovative projects at the NCT Heidelberg, “which in many cases would not come about without this direct funding opportunity“.
By the way: In the face of Covid-19, Proteona is currently pushing forward the production of antiviral antibodies based on ESCAPE single-cell sequencing and bioinformatics. Also, Proteona is part of Aescuvest’s #CrowdBeatsCorona campaign.
The SARS-CoV-2 virus particularly puts immunocompromised individuals at risk, such as those with cancer. Proteona puts its experience in this field at the service of research to develop antibody therapies for Covid-19 patients. Investors can participate in the campaign at aescuvest.de from mid-July.